GlassScriptPhysician profile
Allison Spagnoletti
NPI 1134199938
$8,586.07
in general payments reported to CMS, 2019-2025
47 companies · $1,364 in 2025
The $1,364 reported for 2025 was more than what 88% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,259 · 2022: $1,744 · 2023: $1,709 · 2024: $1,510 · 2025: $1,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,582.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,508.98 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $919.05 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $779.16 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $686.61 | 2021-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $653.66 | 2021-2025 | |
| Glaxosmithkline, LLC. | $537.18 | 2021-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Abbvie INC. | $476.11 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $250.52 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $208.02 | 2021-2024 | Myrbetriq, Veozah |
| Biohaven Pharmaceuticals, INC. | $199.24 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.96 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.46 | 2021-2023 | Jardiance, Synjardy, Glyxambi |
| Novartis Pharmaceuticals Corporation | $156.80 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $156.79 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $154.70 | 2021-2024 | Gvoke Hypopen |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Spagnoletti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.